OptraSCAN, Inc. – Trademark Portfolio

Entity Type: 03

OptraSCAN, Inc. holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 6 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include IMAGEPATH, OPTRASCAN, and ON-DEMAND DIGITAL PATHOLOGY. The owner is based in Cupertino, CA.

10171 Carmen Road

Cupertino, CA 95014

9 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

OptraSCAN, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (6 filings)

Scientific and technological services; industrial analysis and research services

10
Medical Apparatus (3 filings)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does OptraSCAN, Inc. have?

OptraSCAN, Inc. has 9 U.S. trademarks filed with the USPTO. Of these, 4 registered, 5 cancelled.

What trademark classes does OptraSCAN, Inc. file in?

OptraSCAN, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 10 (Medical Apparatus). Class 42 covers scientific and technological services; industrial analysis and research services.

What are OptraSCAN, Inc.'s most well-known trademarks?

OptraSCAN, Inc.'s registered trademark portfolio includes well-known marks such as IMAGEPATH, OPTRASCAN, and ON-DEMAND DIGITAL PATHOLOGY. These are among 4 currently registered trademarks in the portfolio.

What is OptraSCAN, Inc.'s trademark registration success rate?

OptraSCAN, Inc. has a 44% trademark registration rate, with 4 out of 9 resolved applications resulting in successful registration. Currently, 0 applications are pending review.